Results 11 to 20 of about 4,921,476 (300)

Immunotherapy of lung cancer: An update [PDF]

, 2006
In Germany lung cancer is the leading cause of cancer-associated death in men. Surgery, chemotherapy and radiation may enhance survival of patients suffering from lung cancer but the enhancement is typically transient and mostly absent with advanced ...
Hatz, R. A., Jauch, Karl-Walter, van den Engel, N.K., Fox, B.A., Grützner, S., Hatz, R.A., Rüttinger, D., Fox, B. A., Jauch, K.-W., Winter, H., van den Engel, N. K., Schendel, D. J., Pohlac, H., Pohla, H., Schlemmer, M., Schendel, D.J.   +15 more
core   +1 more source

MDT Treatment of Small Cell Lung Cancer Complicated with Adenocarcinoma: 
A Case Report and Literature Review

Chinese Journal of Lung Cancer, 2021
Small cell lung cancer (SCLC) is the most malignant lung cancer with the highest mortality. At present, the first-line standard treatment is still based on Etoposide and Platinum chemotherapy.
Zihan QU, Jiewei LIU, Feng LUO, Lu LI, Lingling ZHU, Qinghua ZHOU   +5 more
doaj   +1 more source

Chronic obstructive pulmonary disease: a complex comorbidity of lung cancer [PDF]

, 2011
Chronic obstructive pulmonary disease (COPD) is a major burden throughout the world. It is associated with a significantly increased incidence of lung cancer and may influence treatment options and outcome.
Derek Grose MRCP, FRCR, Robert Milroy, Grose, Derek, Milroy, Robert   +3 more
core   +1 more source

Lung Cancer in Pulmonary Fibrosis: Tales of Epithelial Cell Plasticity [PDF]

, 2011
Lung epithelial cells exhibit a high degree of plasticity. Alterations to lung epithelial cell function are critically involved in several chronic lung diseases such as pulmonary fibrosis.
Königshoff, M., Melanie Königshoff, Königshoff, Melanie   +2 more
core   +1 more source

EGFR-TKI ADR Management Chinese Expert Consensus

Chinese Journal of Lung Cancer, 2019
ErbB receptor tyrosine kinase inhibitors (EGFR-TKI), gefitinib, erlotinib, icotinib and aftinib, which are approved as a frontline treatment for patients with non-small cell lung cancer (NSCLC) who have tumors harboring EGFR mutations in China.
Chinese Society of Lung Cancer, Chinese Anti-Cancer Association
doaj   +1 more source

Patient-reported outcomes with durvalumab, with or without tremelimumab, plus chemotherapy as first-line treatment for metastatic non-small-cell lung cancer (POSEIDON)

, 2023
Objectives: In the phase 3 POSEIDON study, first-line tremelimumab plus durvalumab and chemotherapy significantly improved overall survival and progression-free survival versus chemotherapy in metastatic non-small-cell lung cancer (NSCLC).
Mann, H., Lim, F.L., Garon, E.B., Saito, H., Farah Louise Lim, Alexander Luft, Melissa Johnson, Edward B Garon, Johnson, M., Xiaojin Shi, Tony Mok, Maen Hussein, Medic, N., Mok, T., Nenad Medic, Cho, B.C., Cheng-Ta Yang, Jorge Alatorre-Alexander, Solange Peters, Geater, S.L., Araujo, L.H., Grygorii Ursol, Luiz Henrique Araujo, Sang-We Kim, Helen Mann, Shi, X., Reinmuth, N., Yang, C.T., Luft, A., Niels Reinmuth, Haruhiro Saito, Byoung Chul Cho, Peters, S., Ursol, G., Kim, S.W., Alatorre-Alexander, J., Hussein, M., Sarayut Lucien Geater   +37 more
core   +1 more source

Research Progress of Epigenetics in Pathogenesis and Treatment of Malignant Tumors

Chinese Journal of Lung Cancer, 2020
Epigenetic modification is closely related to the occurrence and development of tumors. It mainly regulates gene function and expression level through DNA methylation, histone modification, regulation of non-coding RNA and chromatin structure ...
Pan WANG, Honglin ZHAO, Fan REN, Qingchun ZHAO, Ruifeng SHI, Xingyu LIU, Jinghao LIU, Yongwen LI, Ying LI, Hongyu LIU, Jun CHEN   +10 more
doaj   +1 more source

Symptom trajectories during chemotherapy in patients with non‐small cell lung cancer (NSCLC) and the function of prolonging low dose dexamethasone in promoting enhanced recovery after chemotherapy

Thoracic Cancer, 2021
Background Lung cancer, mainly non‐small cell lung cancer (NSCLC), is one of the leading causes of death worldwide. Currently, chemotherapy is still the most significant treatment strategy for NSCLC.
Jinghao Liu, Xingyu Liu, Ming Dong, Honglin Zhao, Mei Li, Hongbing Zhang, Huihui Ji, Yi Shi, Yajie Cui, Di Wu, Gang Chen, Jun Chen   +11 more
doaj   +1 more source

Lung Cancer

Medical Clinics of North America, 2019
Lung cancer is the world's leading cause of cancer death. Screening for lung cancer by low-dose computed tomography improves mortality. Various modalities exist for diagnosis and staging. Treatment is determined by subtype and stage of cancer; there are several personalized therapies that did not exist just a few years ago.
Faria, Nasim, Bruce F, Sabath, George A, Eapen   +2 more
openaire   +5 more sources

EML4-ALK-mediated activation of the JAK2-STAT pathway is critical for non-small cell lung cancer transformation

BMC Pulmonary Medicine, 2021
Background The echinoderm microtubule-associated protein-like-4 anaplastic lymphoma kinase (EML4-ALK) fusion gene was identified in a subset of non-small cell lung cancer (NSCLC) patients. They responded positively to ALK inhibitors.
Ying Li, Yongwen Li, Hongbing Zhang, Ruifeng Shi, Zihe Zhang, Hongyu Liu, Jun Chen   +6 more
doaj   +1 more source